StreetInsider
Log in to your account:
Log in
Signup
Home
EPS Insider
Event Calendar
Conferences
Classic Site
Upgrade to SI Premium - Free Trial
UPDATE: BMO Capital Downgrades Biogen (BIIB) to Market Perform
February 4, 2022 5:13 AM
(Updated - February 4, 2022 6:45 AM EST)
BMO Capital analyst Evan David Seigerman downgraded Biogen (NASDAQ: BIIB) from ...
(Premium-only article. Please sign in or upgrade to SI Premium to view.)
Categories
Analyst Comments
Downgrades
Next Articles
Biogen (BIIB) PT Lowered to $235 at Wells Fargo
February 4, 2022 6:42 AM
Biogen (BIIB) PT Raised to $227 at RBC Capital
February 4, 2022 6:39 AM
Biogen says U.S. FTC, SEC probing Alzheimer's disease drug
February 4, 2022 6:35 AM
Biogen (BIIB) PT Lowered to $290 at Needham & Company
February 4, 2022 6:26 AM
Biogen (BIIB) PT Lowered to $230 at BofA Securities
February 4, 2022 5:50 AM
Biogen (BIIB) PT Lowered to $285 at Oppenheimer
February 4, 2022 4:40 AM
Biogen (BIIB) PT Lowered to $235 at Barclays
February 4, 2022 4:37 AM
Biogen (BIIB) PT Lowered to $217 at Wolfe Research
February 4, 2022 3:57 AM
Form 10-K BIOGEN INC. For: Dec 31
February 3, 2022 5:27 PM
Biogen (BIIB) PT Lowered to $304 at Stifel
February 3, 2022 11:12 AM
